Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
timolumab
- Development stage
- Phase 2
- Lead developer
- Biotie Therapies
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Timolumab (formerly known as BTT1023) is a fully human monoclonal antibody that targets vascular adhesion protein 1 (VAP-1), also known as amine oxidase copper-containing 3 (AOC3). By binding to VAP-1, timolumab blocks its function as an adhesion molecule, thereby reducing the entry of leukocytes into sites of tissue inflammation. This mechanism is relevant in diseases characterized by chronic inflammation and fibrosis. Timolumab has been investigated primarily for the treatment of primary sclerosing cholangitis, a progressive fibrotic liver disease with limited therapeutic options. The drug has also been studied in patients with rheumatoid arthritis and psoriasis[1][2][4][5][8].
- Other names
- timolumab
02
Targets
AOC3 (Amine oxidase copper-containing 3)
Beyond the preview
Go deeper on timolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on timolumab.